NasdaqGS:HUMABiotechs
A Look At Humacyte (HUMA) Valuation As Symvess Secures Saudi Commitment And Israel Filing
Interest in Humacyte (HUMA) is being shaped by a US$1.475 million minimum purchase commitment for Symvess in Saudi Arabia, along with a Marketing Authorization Application in Israel, both focused on vascular trauma treatment.
See our latest analysis for Humacyte.
The recent Saudi Arabia purchase commitment and Israel filing come at a time when Humacyte's share price return has moved sharply, with a 7 day share price return of 32.51% and a 1 year total shareholder return of 76.42%, suggesting...